Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

Autor: Ahn, Myung J., Kim, Hye R., Yang, James C.H., Han, Ji-Yu, Li, Jacky Yu-Chung., Hochmair, Maximilian J., Chang, Gee-Chen, Delmonte, Angelo, Lee, Ki H., Campelo, Rosario G., Gridelli, Cesare, Spira, Alexander I., Califano, Raffaele, Griesinger, Frank, Ghosh, Sharmistha, Felip, Enriqueta, Kim, Dong-Wan, Liu, Yuyin, Zhang, Pingkuan, Popat, Sanjay, Camidge, D. Ross
Zdroj: In Clinical Lung Cancer December 2022 23(8):720-730
Databáze: ScienceDirect
Externí odkaz: